Spectral Medical Inc. Announces Closing of First Tranche of $14.0 Million Convertible Note Private Placement, Conversion ...
TORONTO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”), is pleased …